ARTIS Ventures

About The Fund

ARTIS Ventures is a San Francisco-based venture capital firm founded in 2002, that focuses on the convergence of technology and biology, known as TechBio. They pride themselves on being the first dedicated fund globally to deploy capital in the field where data, software, AI, machine learning, and deep learning transform human health and well-being. The firm is committed to long-term investments that have a significant impact on human health and wellness, emphasizing scalable medical technologies backed by engineering, AI, and strong datasets with broad indications for healthcare and life sciences. ARTIS Ventures targets a Tech Bio+Health investment thesis which bestows companies with the flexibility to pivot during times of need, exploiting a plethora of indications from a singular biologically engineered approach. This increases the potential for revenue streams, optionality, intellectual property, and flexibility. An engineering-first approach marries computer science with cellular biology empowering personalized therapeutics, efficient drug discovery, and AI-machine led exploration of biological circuitry. ARTIS Ventures seeks opportunities to invest in globally scalable companies that can improve health outcomes or even cure diseases. Its portfolio ranges across diverse sectors, including oncology, immunology, cardiopulmonary and metabolic, neurology and mental health, and AI applications in healthcare. With its significant investment range of up to $40 million, ARTIS Ventures caters to early-stage and seed funding rounds, striving to support companies that can redefine, reinvent, and reshape industries.